The Week Ahead in Life Sciences

研报英文原文证据摘录

The Week Ahead in Life Sciences

(a weekly publication detailing key catalysts in our coverage universe)

June 13, 2026

(dollars in millions)

Events Highlighted in the Coming Month

Company/Event Ticker Rating Mkt cap Timing Anticipated Event

Gossamer Bio GOSS Neutral $79 Mid-June FDA Type B Meeting for seralutinib registrational path in PAH

Viridian Therapeutics VRDN Outperform $1,805 June 30, 2026 PDUFA date for veligrotug in TED

Larimar Therapeutics LRMR Outperform $360 June 2026 BLA submission for nomlabofusp in FA -- potential accelerated approval

Nektar Therapeutics NKTR Neutral $2,006 2Q26 End-of-Phase 2 meeting with FDA for rezpeg in AA

Biogen BIIB Neutral $29,535 2Q26 Top-line Phase 2 results of BIIB091 (peripheral BTKi in MS)

Larimar Therapeutics LRMR Outperform $360 2Q26 Report OL study data supporting BLA for nomlabofusp in Friedreich’s Ataxia (FA)

Edgewise Therapeutics EWTX Outperform $3,747 2Q26 Phase 2 CIRRUS-HCM data for EDG-7500 in oHCM / nHCM patients (12-week data)

Vera Therapeutics VERA Neutral $2,459 2Q26 Initial Phase 2 basket trial data for atacicept in expanded IgAN and other autoimmune kidney diseases

Novocure Ltd NVCR Neutral $2,059 2Q26 Data from Ph 3 TRIDENT study of Optune Gio concurrent with radiotherapy and temozolomide in 1L GBM

Bicara Therapeutics BCAX Outperform $1,425 2Q26 Long-term follow up data from Ph 1b study of ficerafusp alfa + pembrolizumab in HPV-negative 1L R/M HNSCC

TScan Therapeutics TCRX Outperform $60 2Q26 Initiate registrational trial for TSC-101 in heme malignancies

TScan Therapeutics TCRX Outperform $60 2Q26 Initial results from Cohort C of ALLOHA (commercial-ready manufacturing process)

Odyssey Therapeutics ODTX Outperform $797 2Q26 Development candidate nomination for OD-004 (TSLPxIL-33)